logo transparent gif
top_white_spacer
Home Latest Stock Forum Topics MyCorner - Personal Stocks Porfolio Stock Lists Investor Insights Investor Research & Links Dynamic Stock Charting FREE Registration About Us top spacer top spacer
 User Password Auto-Login
Enter Stock
 
righttip
branding

Back
First   < Newer   6041-6060 of 23254   Older>   Last  
Latest Forum Topics / Genting Sing    Last:0.605    -0.005  Post Reply
Genting SP Next Move
lighter87
Master
16-May-2020 11:53     
 
lighter87 About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		That's Malaysia genting.

Trader130      ( Date: 16-May-2020 09:37) Posted:



KUALA LUMPUR (May 15): Genting Bhd' s indirect 93.04%-owned subsidiary DNA Electronics Ltd (DNAe), a sequencing company that is currently developing novel diagnostics for use at the point of need, today announced that its internal tests by using LiDia-SEQ&trade sequencing technology to identify SARS-CoV-2 indicated positive results. 

The SARS-CoV-2 coronavirus is the cause of the Covid-19 pandemic that is  currently causing extensive mortality, morbidity and disruption globally. 

In a statement, DNAe president Samuel Reed said these early test results demonstrate the potential for LiDia-SEQ&trade to identify viruses such as SARS-CoV-2. 

 

 

 

The team is encouraged and all the more driven in our mission to contribute to pandemic responses. Our platform could play a vital role in helping contain future outbreaks by bringing sequencing-based diagnostics to the front line. We are continuing to develop the assay, with a view to working with patient samples soon,&rdquo Reed said. 

DNAe executive chairman and cofounder Professor Christofer Toumazou, who is also Regius Professor of Engineering at Imperial College London, commented: &ldquo Covid-19 has accentuated the desperate need for accurate and rapid infectious disease diagnostics."

" This need will only heighten over the coming months as the pandemic persists, as societies make steps to reopen, and as we have the onset of other seasonal illnesses side by side with the pandemic. By rapidly providing accurate, actionable information, we believe LiDia-SEQ&trade offers numerous benefits to controlling infectious disease outbreaks," Toumazou said. 

LiDia-SEQ&trade is the world&rsquo s first rapid and direct-from-specimen diagnostic sequencing platform. It is in development for multiple applications including diagnostics for infectious diseases and cancer, with the support of major investor Genting and the Biomedical Advanced Research and Development Authority (BARDA). 

BARDA, a division of the Assistant Secretary for Preparedness and Response (ASPR) in the US Department of Health and Human Services, has awarded DNAe a contract worth up to US$51.9 million if all options are awarded, to support the development of the system, initially for antimicrobial-resistant infections.  The  platform and assay were recently granted Breakthrough Device designation by the USA Food and Drug Administration.

Genting chairman and chief executive and Visiting Professor at Imperial College London Tan Sri Lim Kok Thay said: &ldquo We have long-recognised that DNAe&rsquo s unique technology is the approach of the future and is critical to many medical needs, including pandemics.

" We are excited by the early results and this is an important step forward to bringing sequencing to the front line as a rapid, cartridge-contained test that allows frontline workers to easily detect the virus and accurately identify it.&rdquo

DNAe&rsquo s technology can provide many potential benefits to controlling infectious disease outbreaks. Due to its high accuracy and sensitivity, by using sequencing, the causative virus or even particular strains can be identified. 

Also, it can deliver rapid and cost-effective results by obtaining results within hours instead of days, which allows for rapid triaging, e.g. isolating infected individuals, safely clearing non-infected patients from isolation, and potentially enabling frontline workers to return to work. 

Ease of use of the technology' s closed cartridge format will ensure minimal operator interaction and new operators can be rapidly trained.

The technology,  which is a benchtop device, is also available at the point of need. It  will be easily deployable to temporary hospitals and other environments to support triage, and its fast turnaround time allows for high volume of testing.

The technology also allows multi-usage as  sequencing can identify many different viruses and strains, be they routine diseases or outbreaks, in a single test, which will help to earlier detect and contain new hotspots or outbreaks and distinguish new infectious diseases from routine respiratory disease.

At the time of writing, Genting shares rose one sen or 0.25% at RM3.95, bringing it some market capitalisation of RM15.21 billion. Some 2.34 million shares were traded.

 Useful To Me  Not Useful To Me
sengsk
Elite
16-May-2020 11:52     
 
sengsk About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Might also good time to sell and short.
Personal view only.
 

Trader130      ( Date: 16-May-2020 09:40) Posted:

Expect GAP up.... on Monday 

Longtermer      ( Date: 15-May-2020 15:54) Posted:


 
Genting Singapore - Tough Times Ahead TAKE PROFIT Now
(RHB Analyst Update)
 
Genting Singapore&rsquo s 1Q20 results are largely in line with our forecasts, with EBITDA plunging 55% y-o-y to SGD147m. See Genting Singapore Announcements. We see more downside risks at current Genting Singapore share price levels, as the recovery may not be as swift if the COVID-19 pandemic drags on.
Management has extended its pessimistic outlook to the rest of FY20.
 
Downgrade to TAKE PROFIT from Buy, SGD0.64 Target Price, 12% downside with 5.5% FY20F yield.
Nevertheless, Genting Singapore&rsquo s strong balance sheet should enable it to tide through this difficult time. We recommend that investors buy on dips.
 
Harder times to come
 
&bull                     Genting Singapore (SGX:G13)' s 1Q20 results are in line, as we expect a poor set of FY20 numbers, in view of the pandemic. We expect 2Q20 numbers to be impacted further, as Genting Singapore halted almost all operations to comply with Singapore&rsquo s &ldquo circuit breaker&rdquo regulations.
&bull                     Even though the &ldquo circuit breaker&rdquo is expected to end on 1 Jun, we believe restrictions will only be lifted in phases &ndash and Genting Singapore&rsquo s operations may remain suspended in the near term.
Prolonged pandemic poses downside risks.
&bull                     At current valuations, we see downside risks arising from a slower recovery in Genting Singapore&rsquo s performance, if the pandemic remains widespread and protracted. While the Government is in discussions with other countries on lifting travel restrictions with safeguards in place, we think that will take some time to implement as COVID-19 continues its global rampage.
&bull                     Countries with declining COVID-19 cases will also need to be monitored, for any resurgence in cases after their lockdowns ease. As such, we believe short-term international travel for leisure could take a longer time to resume. Tourism may also not recover in a significant way, as travellers remain wary of potential infection.
&bull                     See also previous report: Genting Singapore - RHB Invest 2020-03-20: Write-Off 2020, Look Forward To 2021.
 
We recommend that investors TAKE PROFIT
&bull                     We recommend that investors TAKE PROFIT at the current share price levels, as a swift recovery is unlikely in the near term.
&bull                     Nevertheless, we note that Genting Singapore has a strong balance sheet and net cash of SGD3.7bn as at 31 Dec 2019 &ndash which should help it weather through the long winter. We recommend longer-term investors to accumulate on dips, if Genting Singapore Share Price falls below SGD0.59, which implies c.5.5x average FY20- 21F EV/EBITDA (or -1SD from the mean)
&bull                     Genting Singapore continues to be engaged in the ongoing request-for-concept process for the integrated resort in Yokohama, Japan. The request-for-proposal will be made in 2H20.
 
Juliana Cai
https://www.rhbinvest.com.sg

 


 Useful To Me  Not Useful To Me


tangoanna
Master
16-May-2020 11:12     
 
tangoanna About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		No high rollers coming in. No revenue from hotel. SELL
 Useful To Me  Not Useful To Me
danger
Supreme
16-May-2020 11:10     
 
danger About Contact  Quote this Post! Style: Combined   Mood: cool
  x 0
  x 0

 Alert Admin 		Some say sell.. some say buy ??!!
 Useful To Me  Not Useful To Me
Trader130
Supreme
16-May-2020 11:03     
 
Trader130 About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		If approve by US then gS price gonna shoot up .. anytime can happen 

lorann      ( Date: 16-May-2020 10:49) Posted:

Looks like no good news for the next 2 months
 Useful To Me  Not Useful To Me


lorann
Senior
16-May-2020 10:49     
 
lorann About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Looks like no good news for the next 2 months
 Useful To Me  Not Useful To Me
Trader130
Supreme
16-May-2020 10:08     
 
Trader130 About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Same as  biolidics company shoot up high .. 
 Useful To Me  Not Useful To Me
Trader130
Supreme
16-May-2020 09:40     
 
Trader130 About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Expect GAP up.... on Monday 

Longtermer      ( Date: 15-May-2020 15:54) Posted:


 
Genting Singapore - Tough Times Ahead TAKE PROFIT Now
(RHB Analyst Update)
 
Genting Singapore&rsquo s 1Q20 results are largely in line with our forecasts, with EBITDA plunging 55% y-o-y to SGD147m. See Genting Singapore Announcements. We see more downside risks at current Genting Singapore share price levels, as the recovery may not be as swift if the COVID-19 pandemic drags on.
Management has extended its pessimistic outlook to the rest of FY20.
 
Downgrade to TAKE PROFIT from Buy, SGD0.64 Target Price, 12% downside with 5.5% FY20F yield.
Nevertheless, Genting Singapore&rsquo s strong balance sheet should enable it to tide through this difficult time. We recommend that investors buy on dips.
 
Harder times to come
 
&bull                     Genting Singapore (SGX:G13)' s 1Q20 results are in line, as we expect a poor set of FY20 numbers, in view of the pandemic. We expect 2Q20 numbers to be impacted further, as Genting Singapore halted almost all operations to comply with Singapore&rsquo s &ldquo circuit breaker&rdquo regulations.
&bull                     Even though the &ldquo circuit breaker&rdquo is expected to end on 1 Jun, we believe restrictions will only be lifted in phases &ndash and Genting Singapore&rsquo s operations may remain suspended in the near term.
Prolonged pandemic poses downside risks.
&bull                     At current valuations, we see downside risks arising from a slower recovery in Genting Singapore&rsquo s performance, if the pandemic remains widespread and protracted. While the Government is in discussions with other countries on lifting travel restrictions with safeguards in place, we think that will take some time to implement as COVID-19 continues its global rampage.
&bull                     Countries with declining COVID-19 cases will also need to be monitored, for any resurgence in cases after their lockdowns ease. As such, we believe short-term international travel for leisure could take a longer time to resume. Tourism may also not recover in a significant way, as travellers remain wary of potential infection.
&bull                     See also previous report: Genting Singapore - RHB Invest 2020-03-20: Write-Off 2020, Look Forward To 2021.
 
We recommend that investors TAKE PROFIT
&bull                     We recommend that investors TAKE PROFIT at the current share price levels, as a swift recovery is unlikely in the near term.
&bull                     Nevertheless, we note that Genting Singapore has a strong balance sheet and net cash of SGD3.7bn as at 31 Dec 2019 &ndash which should help it weather through the long winter. We recommend longer-term investors to accumulate on dips, if Genting Singapore Share Price falls below SGD0.59, which implies c.5.5x average FY20- 21F EV/EBITDA (or -1SD from the mean)
&bull                     Genting Singapore continues to be engaged in the ongoing request-for-concept process for the integrated resort in Yokohama, Japan. The request-for-proposal will be made in 2H20.
 
Juliana Cai
https://www.rhbinvest.com.sg

 

 Useful To Me  Not Useful To Me


uiop1223
Supreme
16-May-2020 09:40     
 
uiop1223 About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Not material news. Testing is not game changer. So many testing available. Too many suppliers on testing.

Unless Genting says it found a vaccine + pass all tests and safe to use worldwide.
 Useful To Me  Not Useful To Me
Trader130
Supreme
16-May-2020 09:37     
 
Trader130 About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin

KUALA LUMPUR (May 15): Genting Bhd' s indirect 93.04%-owned subsidiary DNA Electronics Ltd (DNAe), a sequencing company that is currently developing novel diagnostics for use at the point of need, today announced that its internal tests by using LiDia-SEQ&trade sequencing technology to identify SARS-CoV-2 indicated positive results. 

The SARS-CoV-2 coronavirus is the cause of the Covid-19 pandemic that is  currently causing extensive mortality, morbidity and disruption globally. 

In a statement, DNAe president Samuel Reed said these early test results demonstrate the potential for LiDia-SEQ&trade to identify viruses such as SARS-CoV-2. 

 

 

 

The team is encouraged and all the more driven in our mission to contribute to pandemic responses. Our platform could play a vital role in helping contain future outbreaks by bringing sequencing-based diagnostics to the front line. We are continuing to develop the assay, with a view to working with patient samples soon,&rdquo Reed said. 

DNAe executive chairman and cofounder Professor Christofer Toumazou, who is also Regius Professor of Engineering at Imperial College London, commented: &ldquo Covid-19 has accentuated the desperate need for accurate and rapid infectious disease diagnostics."

" This need will only heighten over the coming months as the pandemic persists, as societies make steps to reopen, and as we have the onset of other seasonal illnesses side by side with the pandemic. By rapidly providing accurate, actionable information, we believe LiDia-SEQ&trade offers numerous benefits to controlling infectious disease outbreaks," Toumazou said. 

LiDia-SEQ&trade is the world&rsquo s first rapid and direct-from-specimen diagnostic sequencing platform. It is in development for multiple applications including diagnostics for infectious diseases and cancer, with the support of major investor Genting and the Biomedical Advanced Research and Development Authority (BARDA). 

BARDA, a division of the Assistant Secretary for Preparedness and Response (ASPR) in the US Department of Health and Human Services, has awarded DNAe a contract worth up to US$51.9 million if all options are awarded, to support the development of the system, initially for antimicrobial-resistant infections.  The  platform and assay were recently granted Breakthrough Device designation by the USA Food and Drug Administration.

Genting chairman and chief executive and Visiting Professor at Imperial College London Tan Sri Lim Kok Thay said: &ldquo We have long-recognised that DNAe&rsquo s unique technology is the approach of the future and is critical to many medical needs, including pandemics.

" We are excited by the early results and this is an important step forward to bringing sequencing to the front line as a rapid, cartridge-contained test that allows frontline workers to easily detect the virus and accurately identify it.&rdquo

DNAe&rsquo s technology can provide many potential benefits to controlling infectious disease outbreaks. Due to its high accuracy and sensitivity, by using sequencing, the causative virus or even particular strains can be identified. 

Also, it can deliver rapid and cost-effective results by obtaining results within hours instead of days, which allows for rapid triaging, e.g. isolating infected individuals, safely clearing non-infected patients from isolation, and potentially enabling frontline workers to return to work. 

Ease of use of the technology' s closed cartridge format will ensure minimal operator interaction and new operators can be rapidly trained.

The technology,  which is a benchtop device, is also available at the point of need. It  will be easily deployable to temporary hospitals and other environments to support triage, and its fast turnaround time allows for high volume of testing.

The technology also allows multi-usage as  sequencing can identify many different viruses and strains, be they routine diseases or outbreaks, in a single test, which will help to earlier detect and contain new hotspots or outbreaks and distinguish new infectious diseases from routine respiratory disease.

At the time of writing, Genting shares rose one sen or 0.25% at RM3.95, bringing it some market capitalisation of RM15.21 billion. Some 2.34 million shares were traded.
 Useful To Me  Not Useful To Me
Trader130
Supreme
16-May-2020 09:34     
 
Trader130 About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		BB coming in later 
 Useful To Me  Not Useful To Me
danger
Supreme
15-May-2020 16:26     
 
danger About Contact  Quote this Post! Style: Combined   Mood: cool
  x 0
  x 0

 Alert Admin 		NOT MOVING !!??
 Useful To Me  Not Useful To Me


TA_Expert
Supreme
15-May-2020 16:23     
 
TA_Expert About Contact  Quote this Post!  
Yells: "The World has changed"
  x 0
  x 0

 Alert Admin 		Yes, it is tightly controlled, very obvious.

Unless the godfather allows it, nobody can force it down.

lighter87      ( Date: 15-May-2020 11:08) Posted:

Still tightly controlled. Looks at the market depth. Big boss dictate the price to fall

gravity8888      ( Date: 15-May-2020 11:06) Posted:

Finally the selling is here


 Useful To Me  Not Useful To Me
Andynkl
Senior
15-May-2020 16:09     
 
Andynkl About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Yes.. Expected but the share price is still holding well at 70s. Still waiting...

Longtermer      ( Date: 15-May-2020 15:54) Posted:


 
Genting Singapore - Tough Times Ahead TAKE PROFIT Now
(RHB Analyst Update)
 
Genting Singapore&rsquo s 1Q20 results are largely in line with our forecasts, with EBITDA plunging 55% y-o-y to SGD147m. See Genting Singapore Announcements. We see more downside risks at current Genting Singapore share price levels, as the recovery may not be as swift if the COVID-19 pandemic drags on.
Management has extended its pessimistic outlook to the rest of FY20.
 
Downgrade to TAKE PROFIT from Buy, SGD0.64 Target Price, 12% downside with 5.5% FY20F yield.
Nevertheless, Genting Singapore&rsquo s strong balance sheet should enable it to tide through this difficult time. We recommend that investors buy on dips.
 
Harder times to come
 
&bull                     Genting Singapore (SGX:G13)' s 1Q20 results are in line, as we expect a poor set of FY20 numbers, in view of the pandemic. We expect 2Q20 numbers to be impacted further, as Genting Singapore halted almost all operations to comply with Singapore&rsquo s &ldquo circuit breaker&rdquo regulations.
&bull                     Even though the &ldquo circuit breaker&rdquo is expected to end on 1 Jun, we believe restrictions will only be lifted in phases &ndash and Genting Singapore&rsquo s operations may remain suspended in the near term.
Prolonged pandemic poses downside risks.
&bull                     At current valuations, we see downside risks arising from a slower recovery in Genting Singapore&rsquo s performance, if the pandemic remains widespread and protracted. While the Government is in discussions with other countries on lifting travel restrictions with safeguards in place, we think that will take some time to implement as COVID-19 continues its global rampage.
&bull                     Countries with declining COVID-19 cases will also need to be monitored, for any resurgence in cases after their lockdowns ease. As such, we believe short-term international travel for leisure could take a longer time to resume. Tourism may also not recover in a significant way, as travellers remain wary of potential infection.
&bull                     See also previous report: Genting Singapore - RHB Invest 2020-03-20: Write-Off 2020, Look Forward To 2021.
 
We recommend that investors TAKE PROFIT
&bull                     We recommend that investors TAKE PROFIT at the current share price levels, as a swift recovery is unlikely in the near term.
&bull                     Nevertheless, we note that Genting Singapore has a strong balance sheet and net cash of SGD3.7bn as at 31 Dec 2019 &ndash which should help it weather through the long winter. We recommend longer-term investors to accumulate on dips, if Genting Singapore Share Price falls below SGD0.59, which implies c.5.5x average FY20- 21F EV/EBITDA (or -1SD from the mean)
&bull                     Genting Singapore continues to be engaged in the ongoing request-for-concept process for the integrated resort in Yokohama, Japan. The request-for-proposal will be made in 2H20.
 
Juliana Cai
https://www.rhbinvest.com.sg

 

 Useful To Me  Not Useful To Me
Longtermer
Elite
15-May-2020 15:54     
 
Longtermer About Contact  Quote this Post! Style: Flexible  
Yells: "A disciplined investor is a wealthy investor"
  x 0
  x 0

 Alert Admin

 
Genting Singapore - Tough Times Ahead TAKE PROFIT Now
(RHB Analyst Update)
 
Genting Singapore&rsquo s 1Q20 results are largely in line with our forecasts, with EBITDA plunging 55% y-o-y to SGD147m. See Genting Singapore Announcements. We see more downside risks at current Genting Singapore share price levels, as the recovery may not be as swift if the COVID-19 pandemic drags on.
Management has extended its pessimistic outlook to the rest of FY20.
 
Downgrade to TAKE PROFIT from Buy, SGD0.64 Target Price, 12% downside with 5.5% FY20F yield.
Nevertheless, Genting Singapore&rsquo s strong balance sheet should enable it to tide through this difficult time. We recommend that investors buy on dips.
 
Harder times to come
 
&bull                     Genting Singapore (SGX:G13)' s 1Q20 results are in line, as we expect a poor set of FY20 numbers, in view of the pandemic. We expect 2Q20 numbers to be impacted further, as Genting Singapore halted almost all operations to comply with Singapore&rsquo s &ldquo circuit breaker&rdquo regulations.
&bull                     Even though the &ldquo circuit breaker&rdquo is expected to end on 1 Jun, we believe restrictions will only be lifted in phases &ndash and Genting Singapore&rsquo s operations may remain suspended in the near term.
Prolonged pandemic poses downside risks.
&bull                     At current valuations, we see downside risks arising from a slower recovery in Genting Singapore&rsquo s performance, if the pandemic remains widespread and protracted. While the Government is in discussions with other countries on lifting travel restrictions with safeguards in place, we think that will take some time to implement as COVID-19 continues its global rampage.
&bull                     Countries with declining COVID-19 cases will also need to be monitored, for any resurgence in cases after their lockdowns ease. As such, we believe short-term international travel for leisure could take a longer time to resume. Tourism may also not recover in a significant way, as travellers remain wary of potential infection.
&bull                     See also previous report: Genting Singapore - RHB Invest 2020-03-20: Write-Off 2020, Look Forward To 2021.
 
We recommend that investors TAKE PROFIT
&bull                     We recommend that investors TAKE PROFIT at the current share price levels, as a swift recovery is unlikely in the near term.
&bull                     Nevertheless, we note that Genting Singapore has a strong balance sheet and net cash of SGD3.7bn as at 31 Dec 2019 &ndash which should help it weather through the long winter. We recommend longer-term investors to accumulate on dips, if Genting Singapore Share Price falls below SGD0.59, which implies c.5.5x average FY20- 21F EV/EBITDA (or -1SD from the mean)
&bull                     Genting Singapore continues to be engaged in the ongoing request-for-concept process for the integrated resort in Yokohama, Japan. The request-for-proposal will be made in 2H20.
 
Juliana Cai
https://www.rhbinvest.com.sg

 
 Useful To Me  Not Useful To Me
Longtermer
Elite
15-May-2020 11:33     
 
Longtermer About Contact  Quote this Post! Style: Flexible  
Yells: "A disciplined investor is a wealthy investor"
  x 0
  x 0

 Alert Admin
Rightly be .. and more coming.
Many blue chips trading at 20% discount NAV.
Right value 55c thereabouts for now.  Dyodd.

 
 Useful To Me  Not Useful To Me
lighter87
Master
15-May-2020 11:08     
 
lighter87 About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Still tightly controlled. Looks at the market depth. Big boss dictate the price to fall

gravity8888      ( Date: 15-May-2020 11:06) Posted:

Finally the selling is here

 Useful To Me  Not Useful To Me
gravity8888
Supreme
15-May-2020 11:06     
 
gravity8888 About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Finally the selling is here
 Useful To Me  Not Useful To Me
survivor
Member
15-May-2020 10:51     
 
survivor About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Let go while u can. Run!
 Useful To Me  Not Useful To Me
ysh2006
Supreme
14-May-2020 19:22     
 
ysh2006 About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Genting worth 66.5c only (NVA) ? Share price maintained by hidden hands only.

shortking      ( Date: 14-May-2020 15:55) Posted:

quite a steep drop lets see how this will move

Longtermer      ( Date: 14-May-2020 15:42) Posted:


Based on my estimates,
2020 Q1 Nett profit is about $30m to $40m
The drop will be 83% YOY.

Tourists arrival dried up since March till now and possibly only see some coming back slowly from  September onward ??

Both Q2 ( Apr to June 2020 ) and Q3 (July to Sept 2020 ) will see heavy losses while Q4 may improve if Covid19 can be controlled and tourists return.
The FY 2020 will see heavy losses as guided by CEO in his yesterday statement.

NTA is 66.8c. What is the right valuation for now?
Dyodd. Trade w care.
 


 Useful To Me  Not Useful To Me
                                                         First   < Newer   6041-6060 of 23254   Older>   Last  



ShareJunction Version: 27 Nov 2020 ver- All Rights Reserved. Copyright ShareJunction Pte. Ltd. Disclaimer: All prices from are delayed. ShareJunction does not provide you with any financial advice. We are not into the business of providing any investment advice. See our Terms and Conditions and Privacy Policy of using this website. Data is delayed for varying periods of time depending on the exchange, but for at least 15 minutes. Copyright © SIX Financial Information Ltd. and its licensors. All Rights reserved. Further distribution and use by third parties prohibited. SIX Financial Information and its licensors make no warranty for information displayed and accept no liability for data and prices. SIX Financial Information reserves the right to adapt and/or alter this website at any time without prior notice.

Web design by FoundationFlux. Hosted with Signetique Cloud.